Lucira Health (NASDAQ:LHDXQ – Get Rating) is one of 42 publicly-traded companies in the "Diagnostic substances" industry, but how does it weigh in compared to its peers? We will compare Lucira Health to similar companies based on the strength of its valuation, risk, analyst recommendations, profitability, dividends, earnings and institutional ownership.
Risk and Volatility
Lucira Health has a beta of 3.36, indicating that its stock price is 236% more volatile than the S&P 500. Comparatively, Lucira Health's peers have a beta of 1.37, indicating that their average stock price is 37% more volatile than the S&P 500.
Get Lucira Health alerts:Profitability
This table compares Lucira Health and its peers' net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Lucira Health | -67.54% | -13.55% | -8.47% |
| Lucira Health Competitors | -1,437.85% | -124.65% | -30.99% |
Valuation and Earnings
This table compares Lucira Health and its peers top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Lucira Health | $93.06 million | -$64.83 million | -0.05 |
| Lucira Health Competitors | $452.45 million | $9.16 million | -52.12 |
Lucira Health's peers have higher revenue and earnings than Lucira Health. Lucira Health is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
Analyst Recommendations
This is a summary of recent recommendations and price targets for Lucira Health and its peers, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Lucira Health | 0 | 0 | 0 | 0 | N/A |
| Lucira Health Competitors | 362 | 626 | 1235 | 19 | 2.41 |
As a group, "Diagnostic substances" companies have a potential upside of 37.52%. Given Lucira Health's peers higher possible upside, analysts plainly believe Lucira Health has less favorable growth aspects than its peers.
Institutional & Insider Ownership
57.0% of Lucira Health shares are held by institutional investors. Comparatively, 45.4% of shares of all "Diagnostic substances" companies are held by institutional investors. 30.4% of Lucira Health shares are held by company insiders. Comparatively, 14.1% of shares of all "Diagnostic substances" companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Summary
Lucira Health beats its peers on 7 of the 10 factors compared.
Lucira Health Company Profile
(Get Rating)
Lucira Health Inc. is a medical technology company. It is focused on the development and commercialization of transformative and infectious disease test kits. Lucira Health Inc. is based in Emeryville, California.
Receive News & Ratings for Lucira Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lucira Health and related companies with MarketBeat.com's FREE daily email newsletter.